BR112017019955A2 - composição medicinal para o tratamento de infecção do trato urinário (uti) - Google Patents

composição medicinal para o tratamento de infecção do trato urinário (uti)

Info

Publication number
BR112017019955A2
BR112017019955A2 BR112017019955A BR112017019955A BR112017019955A2 BR 112017019955 A2 BR112017019955 A2 BR 112017019955A2 BR 112017019955 A BR112017019955 A BR 112017019955A BR 112017019955 A BR112017019955 A BR 112017019955A BR 112017019955 A2 BR112017019955 A2 BR 112017019955A2
Authority
BR
Brazil
Prior art keywords
tannins
composition
uti
urinary tract
tract infection
Prior art date
Application number
BR112017019955A
Other languages
English (en)
Inventor
B Howell Amy
G Krueger Christian
Shapland Howard
D Reed Jess
Glickman Scott
Original Assignee
Synesis Llc
Uropharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synesis Llc, Uropharma Ltd filed Critical Synesis Llc
Publication of BR112017019955A2 publication Critical patent/BR112017019955A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

é fornecida uma composição farmacêutica para uso em um método de prevenção ou tratamento de uma infecção do trato urinário (uti), cistite crônica, bexiga hiperativa, obstrução parcial da bexiga ou uretrite, a dita composição compreendendo um ou mais taninos oligoméricos selecionados a partir de proantocianidinas e/ou taninos hidrolisáveis em que, no dito método, a dita composição é administrada através da via intrauretral, intravesical, intrauretral e/ou intrarrenal, bem como uma composição farmacêutica para uso em um método de prevenção ou tratamento de câncer da bexiga em que, no dito método, a dita composição é administrada através da via intravesical, a dita composição compreendendo um ou mais taninos oligoméricos selecionados a partir de proantocianidinas e/ou taninos hidrolisáveis, em que os ditos taninos são ligados a um agente anticâncer e/ou lipossomas que contêm um agente anticâncer, juntamente com composições relacionadas ao mesmo.
BR112017019955A 2015-03-19 2016-03-18 composição medicinal para o tratamento de infecção do trato urinário (uti) BR112017019955A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562135353P 2015-03-19 2015-03-19
GBGB1506526.1A GB201506526D0 (en) 2015-04-17 2015-04-17 Medicinal composition
US201662294047P 2016-02-11 2016-02-11
PCT/EP2016/055933 WO2016146806A1 (en) 2015-03-19 2016-03-18 Medicinal composition for treating urinary tract infection (uti)

Publications (1)

Publication Number Publication Date
BR112017019955A2 true BR112017019955A2 (pt) 2018-06-19

Family

ID=53298731

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019955A BR112017019955A2 (pt) 2015-03-19 2016-03-18 composição medicinal para o tratamento de infecção do trato urinário (uti)

Country Status (18)

Country Link
US (2) US10772901B2 (pt)
EP (1) EP3271016B1 (pt)
JP (1) JP6794381B2 (pt)
KR (1) KR20180025842A (pt)
CN (2) CN116650473A (pt)
AU (1) AU2016232101B2 (pt)
BR (1) BR112017019955A2 (pt)
CA (1) CA2979958C (pt)
DK (1) DK3271016T3 (pt)
ES (1) ES2811336T3 (pt)
GB (1) GB201506526D0 (pt)
HK (1) HK1248532A1 (pt)
HU (1) HUE050967T2 (pt)
IL (1) IL254587B (pt)
PL (1) PL3271016T3 (pt)
RU (1) RU2017136712A (pt)
SG (1) SG10201908620XA (pt)
WO (1) WO2016146806A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180113128A1 (en) * 2016-10-20 2018-04-26 Isi Life Sciences, Inc. Detection of urinary tract infections
US11389507B2 (en) * 2017-06-14 2022-07-19 Biomedical Research Institute Use of interleukin-4-inducing principle of Schistosoma mansoni eggs for treating pain, interstitial cystitis and/or overactive bladder
CA3159406A1 (en) * 2019-10-28 2021-05-06 Hollister Incorported Urinary catheters and methods for preventing bacterial infections
WO2021106856A1 (ja) * 2019-11-29 2021-06-03 小林製薬株式会社 尿路機能改善用組成物及び膀胱血流改善用組成物
JPWO2021106857A1 (pt) * 2019-11-29 2021-06-03
US20240059713A1 (en) * 2021-02-25 2024-02-22 Synesis Llc Fluorescent proanthocyanidins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646178A (en) 1992-10-09 1997-07-08 Jlb, Inc. Cranberry extract and biologically active compounds derived therefrom
DK1014969T3 (da) * 1997-09-09 2009-03-16 Univ Rutgers Plante-proanthocyanidin-ekstrakt, der er effektiv til inhibering af adhærens af bakterier med P-type fimbriae til overflader
RU2161446C2 (ru) 1997-12-25 2001-01-10 Санкт-Петербургская государственная педиатрическая медицинская академия Способ эндоскопического лечения пузырно-мочеточникового рефлюкса
FR2874826B1 (fr) 2004-09-08 2006-12-22 Pharmatoka Soc Par Actions Sim Nouveaux dispositifs chirurgicaux et/ou medicaux et leur mode d'utilisation
US20070166409A1 (en) * 2006-01-17 2007-07-19 Royds Robert B Therapeutic compositions containing trimethoprim and cranberry extract and methods for treating and preventing urinary tract infections
US8715949B2 (en) 2006-09-07 2014-05-06 The United States Of America, As Represented By The Secretary Of The Navy Applications of the binding interaction of proanthocyanidins with bacteria and bacterial components
EP1902721A1 (fr) * 2006-09-20 2008-03-26 Loïc Renard Compositions médicales et nutritionnelles à base de vaccinium macrocarpon
ES2311403B1 (es) * 2007-06-12 2010-01-12 Consejo Superior De Investigaciones Cientificas Extractos fenolicos de piel de almendra conteniendo procianidinas, propelargonidinas y prodelfinidinas, y su procedimiento de obtencion.
US20090226548A1 (en) * 2008-01-11 2009-09-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition
WO2010078660A1 (en) * 2009-01-12 2010-07-15 The Royal Institution For The Advancement Of Learning/Mcgill University Use of proanthocyanidins as an anti-apoptotic agent and anti-adhesive bacterial agent
RU2392931C1 (ru) 2009-03-23 2010-06-27 Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") Способ лечения бактериального уретрита
RU2405601C1 (ru) 2009-05-19 2010-12-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения злокачественных опухолей мочевого пузыря
US8642088B2 (en) * 2009-09-04 2014-02-04 Wisconsin Alumni Research Foundation Tannin-chitosan composites
WO2011088420A1 (en) * 2010-01-15 2011-07-21 Ocean Spray Cranberries, Inc. Process for extracting compound from cranberry leaves and related products
FR2959938B1 (fr) 2010-05-12 2012-09-07 Gunter Haesaerts Sonde urinaire comportant des proanthocyanidines et son mode d'utilisation
RU2452535C1 (ru) 2010-09-29 2012-06-10 Федеральное государственное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения и социального развития Российской Федерации Способ лечения хронического цистита
US9248154B2 (en) 2012-07-06 2016-02-02 Pom Wonderful, Llc Methods and compositions for treatment of uriniary tract infections
CN102772499B (zh) * 2012-08-22 2014-01-08 贵州威门药业股份有限公司 热淋清颗粒原料的醇提有效部位及其制备方法和用途
RU2670749C9 (ru) 2012-09-18 2018-12-13 ТАРИС Биомедикал ЛЛК Системы доставки лекарственного средства и способы лечения дисфункции опорожнения мочевого пузыря и других расстройств нижних мочевыводящих путей с использованием троспия

Also Published As

Publication number Publication date
SG10201908620XA (en) 2019-11-28
WO2016146806A1 (en) 2016-09-22
CN107635552A (zh) 2018-01-26
CN116650473A (zh) 2023-08-29
IL254587B (en) 2021-08-31
CA2979958A1 (en) 2016-09-22
US20180000853A1 (en) 2018-01-04
PL3271016T3 (pl) 2020-11-30
GB201506526D0 (en) 2015-06-03
IL254587A0 (en) 2017-11-30
RU2017136712A (ru) 2019-04-22
AU2016232101B2 (en) 2020-10-08
HK1248532A1 (zh) 2018-10-19
RU2017136712A3 (pt) 2019-09-12
EP3271016B1 (en) 2020-06-17
KR20180025842A (ko) 2018-03-09
AU2016232101A1 (en) 2017-11-09
EP3271016A1 (en) 2018-01-24
US20210000851A1 (en) 2021-01-07
DK3271016T3 (da) 2020-09-14
JP6794381B2 (ja) 2020-12-02
US10772901B2 (en) 2020-09-15
ES2811336T3 (es) 2021-03-11
HUE050967T2 (hu) 2021-01-28
JP2018508586A (ja) 2018-03-29
CA2979958C (en) 2022-01-18

Similar Documents

Publication Publication Date Title
BR112017019955A2 (pt) composição medicinal para o tratamento de infecção do trato urinário (uti)
BR112018075073A2 (pt) composições nasais de canabidiol
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
BR112018006039A2 (pt) terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma
CO6382172A2 (es) Efectos antitumorales de combinaciones cannabinoides
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015008447A2 (pt) métodos para tratar câncer
BR112019001794A2 (pt) composição de cannabis
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112017008344A2 (pt) extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica.
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
WO2010089128A3 (en) Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112017027836A2 (pt) método para o tratamento de inflamação usando compostos naturais e/ou dieta
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]